Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies
- PMID: 29463286
- PMCID: PMC5819643
- DOI: 10.1186/s12967-018-1417-7
Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies
Abstract
Background: Bronchopulmonary dysplasia (BPD) is the result of a complex process in which several prenatal and/or postnatal factors interfere with lower respiratory tract development, leading to a severe, lifelong disease. In this review, what is presently known regarding BPD pathogenesis, its impact on long-term pulmonary morbidity and mortality and the available preventive and therapeutic strategies are discussed.
Main body: Bronchopulmonary dysplasia is associated with persistent lung impairment later in life, significantly impacting health services because subjects with BPD have, in most cases, frequent respiratory diseases and reductions in quality of life and life expectancy. Prematurity per se is associated with an increased risk of long-term lung problems. However, in children with BPD, impairment of pulmonary structures and function is even greater, although the characterization of long-term outcomes of BPD is difficult because the adults presently available to study have received outdated treatment. Prenatal and postnatal preventive measures are extremely important to reduce the risk of BPD.
Conclusion: Bronchopulmonary dysplasia is a respiratory condition that presently occurs in preterm neonates and can lead to chronic respiratory problems. Although knowledge about BPD pathogenesis has significantly increased in recent years, not all of the mechanisms that lead to lung damage are completely understood, which explains why therapeutic approaches that are theoretically effective have been only partly satisfactory or useless and, in some cases, potentially negative. However, prevention of prematurity, systematic use of nonaggressive ventilator measures, avoiding supraphysiologic oxygen exposure and administration of surfactant, caffeine and vitamin A can significantly reduce the risk of BPD development. Cell therapy is the most fascinating new measure to address the lung damage due to BPD. It is desirable that ongoing studies yield positive results to definitively solve a major clinical, social and economic problem.
Keywords: Bronchopulmonary dysplasia; Lung; Prematurity; Preterm neonates; Respiratory disease; Respiratory tract infection.
Similar articles
-
Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5. Neonatology. 2015. PMID: 26044104 Review.
-
The economic impact of prematurity and bronchopulmonary dysplasia.Eur J Pediatr. 2017 Dec;176(12):1587-1593. doi: 10.1007/s00431-017-3009-6. Epub 2017 Sep 9. Eur J Pediatr. 2017. PMID: 28889192
-
Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.Trials. 2023 May 9;24(1):320. doi: 10.1186/s13063-023-07257-5. Trials. 2023. PMID: 37161488 Free PMC article.
-
Insulin-like growth factor-1 replacement therapy after extremely premature birth: An opportunity to optimize lifelong lung health by preserving the natural sequence of lung development.Paediatr Respir Rev. 2023 Dec;48:24-29. doi: 10.1016/j.prrv.2023.05.001. Epub 2023 May 6. Paediatr Respir Rev. 2023. PMID: 37268507 Review.
-
Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health.Clin Exp Pharmacol Physiol. 2013 Nov;40(11):765-73. doi: 10.1111/1440-1681.12068. Clin Exp Pharmacol Physiol. 2013. PMID: 23414429 Review.
Cited by
-
Hyperoxia exposure induces ferroptosis and apoptosis by downregulating PLAGL2 and repressing HIF-1α/VEGF signaling pathway in newborn alveolar typeII epithelial cell.Redox Rep. 2024 Dec;29(1):2387465. doi: 10.1080/13510002.2024.2387465. Epub 2024 Aug 5. Redox Rep. 2024. PMID: 39102510 Free PMC article.
-
Strategies for cessation of caffeine administration in preterm infants.Cochrane Database Syst Rev. 2024 Jul 24;7(7):CD015802. doi: 10.1002/14651858.CD015802.pub2. Cochrane Database Syst Rev. 2024. PMID: 39045901 Review.
-
[Risk factors for bronchopulmonary dysplasia in twin preterm infants: a multicenter study].Zhongguo Dang Dai Er Ke Za Zhi. 2024 Jun 15;26(6):611-618. doi: 10.7499/j.issn.1008-8830.2312005. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 38926378 Chinese.
-
Incidence and Predictors of Bronchopulmonary Dysplasia Development and Severity Among Preterm Infants Born at 32 Weeks of Gestation or Less.Cureus. 2024 Apr 30;16(4):e59425. doi: 10.7759/cureus.59425. eCollection 2024 Apr. Cureus. 2024. PMID: 38694676 Free PMC article.
-
Association of Fetal Lung Development Disorders with Adult Diseases: A Comprehensive Review.J Pers Med. 2024 Mar 29;14(4):368. doi: 10.3390/jpm14040368. J Pers Med. 2024. PMID: 38672994 Free PMC article. Review.
References
-
- Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379:2162–2172. - PubMed
-
- Natarajan G, Shankaran S. Short- and long-term outcomes of moderate and late preterm infants. Am J Perinatol. 2016;33:305–317. - PubMed
-
- Kotecha SJ, Dunstan FD, Kotecha S. Long term respiratory outcomes of late preterm-born infants. Semin Fetal Neonatal Med. 2012;17:77–81. - PubMed
-
- Kair LR, Leonard DT, Anderson JM. Bronchopulmonary dysplasia. Pediatr Rev. 2012;33:255–256. - PubMed
-
- Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics. 2009;123:1562–1573. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources